Hims & Hers : HIMS

All Hims & Hers Articles

46 Articles

John Seetoo | Feb 11, 2026 at 7:15 AM EST

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created…

Austin Smith | Feb 9, 2026 at 11:59 AM EST

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled…

Douglas A. McIntyre | Feb 9, 2026 at 10:39 AM EST

Hims & Hers Falls Apart, Again

Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year.…

Rich Duprey | Feb 7, 2026 at 9:03 AM EST

FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown

Hims & Hers (NYSE:HIMS) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies against its…

Lee Jackson | Jan 12, 2026 at 8:07 AM EST

Here Are Monday’s Top Wall Street Analyst Research Calls: Airbnb, Akamai, Applied Materials, CoreWeave, CrowdStrike, Datadog, NetFlix, Snowflake, and More

Pre-Market Stock Futures: The futures are trading lower on Monday morning after a strong finish to the week on Friday,…

William Temple | Dec 30, 2025 at 9:15 AM EST

Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty…

Joel South | Nov 3, 2025 at 3:59 PM EST

Live: Hims & Hers Earnings Coverage

Hims & Hers Health (NYSE: HIMS) reports fiscal third-quarter earnings after the close. The telehealth innovator has become one of…

Rich Duprey | Aug 22, 2025 at 12:13 PM EDT

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) has been a trailblazer in…

Rich Duprey | Aug 6, 2025 at 11:35 AM EDT

There Is Only 1 GLP-1 Stock to Buy In 2025

Weighing the Options The introduction of Novo Nordisk’s (NYSE:NVO | NVO Price Prediction) Ozempic revolutionized the fight against obesity, shifting…

Joel South | Aug 5, 2025 at 9:09 AM EDT

Stock Market Live August 5: S&P 500 (VOO) Rises Even As More Tariffs Trouble Looms

This article will be updated throughout the day, so check back often for more daily updates. Tariffs are in the…

Joel South | Aug 4, 2025 at 3:00 PM EDT

Live: Here’s Why Hims & Hers (HIMS) Is Down 10% After Earnings

Hims & Hers (NYSE: HIMS) reports Q2 2025 earnings after the market closes, following a strong Q1 marked by elevated…

Rich Duprey | Jul 29, 2025 at 11:25 AM EDT

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) is watching its stock plummet 20% in morning trading after…

Rich Duprey | Jul 24, 2025 at 10:22 AM EDT

Is Hims & Hers the Newest Meme Stock Darling?

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high…

Rich Duprey | Jul 16, 2025 at 10:55 AM EDT

3 Ridiculously Discounted Growth Stocks to Buy Now

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it…

Omor Ibne Ehsan | Jul 14, 2025 at 10:18 AM EDT

3 Dividend Growth Stocks to Turn $10,000 Into $50,000 by 2035

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon.…

1 2 3 4

Hims & Hers : HIMS

All Hims & Hers Articles

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Hims & Hers Falls Apart, Again

FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown

Here Are Monday’s Top Wall Street Analyst Research Calls: Airbnb, Akamai, Applied Materials, CoreWeave, CrowdStrike, Datadog, NetFlix, Snowflake, and More

Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses

Live: Hims & Hers Earnings Coverage

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

There Is Only 1 GLP-1 Stock to Buy In 2025

Stock Market Live August 5: S&P 500 (VOO) Rises Even As More Tariffs Trouble Looms

Live: Here’s Why Hims & Hers (HIMS) Is Down 10% After Earnings

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Is Hims & Hers the Newest Meme Stock Darling?

3 Ridiculously Discounted Growth Stocks to Buy Now

3 Dividend Growth Stocks to Turn $10,000 Into $50,000 by 2035

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Hims & Hers : HIMS

All Hims & Hers Articles

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Hims & Hers Falls Apart, Again

FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown

Here Are Monday’s Top Wall Street Analyst Research Calls: Airbnb, Akamai, Applied Materials, CoreWeave, CrowdStrike, Datadog, NetFlix, Snowflake, and More

Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses

Live: Hims & Hers Earnings Coverage

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

There Is Only 1 GLP-1 Stock to Buy In 2025

Stock Market Live August 5: S&P 500 (VOO) Rises Even As More Tariffs Trouble Looms

Live: Here’s Why Hims & Hers (HIMS) Is Down 10% After Earnings

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Is Hims & Hers the Newest Meme Stock Darling?

3 Ridiculously Discounted Growth Stocks to Buy Now

3 Dividend Growth Stocks to Turn $10,000 Into $50,000 by 2035

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026